Pharmaceuticals, Biotechnology and Life Sciences
Net Product Revenue for Auryxia Increases to $23.1 Million for Q1’FY19, Up 12.1% from Q1’FY18; Full Enrollment of Phase 3…
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) announced today that Tina Ventura, senior vice president, investor relations, has been named a…
BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration with the LuMind IDSC Foundation (LuMind IDSC) involving use of Cerveau’s…
– Data from FIERCE-22 Phase 2 Trial in Metastatic Bladder Cancer – SAN LEANDRO, Calif.–(BUSINESS WIRE)–Rainier Therapeutics, Inc., a privately-held…
Spending on all U.S. medicines increased 4.5 percent to $344 billion on a net price basis, despite lower price growth,…
Recent Data Presentation Highlights Consistent Complete Response Rate and Strong Durability at Six-Months in Evaluable Patients with Low-Grade Upper Tract…
— Dosed first subjects in Phase 1 study of MGTA-145 first-line mobilization therapy — — Presented updated Phase 2 clinical…
Lisa Mahnke, M.D., Ph.D., joins as Senior Vice President, Head of Clinical, and Terrence West, MBA, joins as Vice President,…
– IW-3718 Phase II data in patients with persistent GERD to be featured in oral presentation – – Data from…
DUBLIN–(BUSINESS WIRE)–The “Global Laryngeal Cancer Therapeutics Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering. The laryngeal cancer therapeutics market…